Abstract
A typical feature of ageing is a chronic, low-grade inflammation characterized by a general increase in the production of proinflammatory cytokines and inflammatory markers (“inflamm-ageing”). This status may slowly damage one or several organs, especially when unfavorable genetic polymorphisms and epigenetic alterations are concomitant, leading to an increased risk of frailty together with the onset of age-related chronic diseases. The contribution of different tissues (adipose tissue, muscle), organs (brain, liver), immune system and ecosystems (gut microbiota) to age-related inflammation (“inflamm-ageing”) will be discussed in this review in the context of its onset/progression leading to site-restricted and systemic effects. Moreover, some of the possible strategies and therapies to counteract the different sources of molecular mediators which lead to the age-related inflammatory phenotype will be presented.
Keywords: Ageing, age-related diseases, immunosenescence, inflammation
Current Pharmaceutical Design
Title: Age-Related Inflammation: the Contribution of Different Organs, Tissues and Systems. How to Face it for Therapeutic Approaches
Volume: 16 Issue: 6
Author(s): E. Cevenini, C. Caruso, G. Candore, M. Capri, D. Nuzzo, G. Duro, C. Rizzo, G. Colonna-Romano, D. Lio, D. Di Carlo, M. G. Palmas, M. Scurti, E. Pini, C. Franceschi and S. Vasto
Affiliation:
Keywords: Ageing, age-related diseases, immunosenescence, inflammation
Abstract: A typical feature of ageing is a chronic, low-grade inflammation characterized by a general increase in the production of proinflammatory cytokines and inflammatory markers (“inflamm-ageing”). This status may slowly damage one or several organs, especially when unfavorable genetic polymorphisms and epigenetic alterations are concomitant, leading to an increased risk of frailty together with the onset of age-related chronic diseases. The contribution of different tissues (adipose tissue, muscle), organs (brain, liver), immune system and ecosystems (gut microbiota) to age-related inflammation (“inflamm-ageing”) will be discussed in this review in the context of its onset/progression leading to site-restricted and systemic effects. Moreover, some of the possible strategies and therapies to counteract the different sources of molecular mediators which lead to the age-related inflammatory phenotype will be presented.
Export Options
About this article
Cite this article as:
Cevenini E., Caruso C., Candore G., Capri M., Nuzzo D., Duro G., Rizzo C., Colonna-Romano G., Lio D., Carlo Di D., Palmas G. M., Scurti M., Pini E., Franceschi C. and Vasto S., Age-Related Inflammation: the Contribution of Different Organs, Tissues and Systems. How to Face it for Therapeutic Approaches, Current Pharmaceutical Design 2010; 16(6) . https://dx.doi.org/10.2174/138161210790883840
DOI https://dx.doi.org/10.2174/138161210790883840 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Central Insulin and Insulin-Like Growth Factor-1 Signaling - Implications for Diabetes Associated Dementia
Current Diabetes Reviews The Finely Regulating Well-defined Functional Polymeric Nanocarriers for Anti-tumor Immunotherapy
Mini-Reviews in Medicinal Chemistry Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Targeting Tumour Metastasis: The Emerging Role of Nanotechnology
Current Medicinal Chemistry MicroRNA Dysregulation in the Myelodysplastic Syndromes
MicroRNA Synthetic Glycopeptides from the Mucin Family as Potential Tools in Cancer Immunotherapy
Current Cancer Drug Targets Designing Prodrugs Based on Special Residues of Human Serum Albumin
Current Topics in Medicinal Chemistry Extraction, Chemical Composition, Antioxidant Property, and <i>In-vitro</i> Anticancer Activity of Silymarin from <i>Silybum marianum</i> on Kb and A549 Cell Lines
Current Drug Discovery Technologies Subject Index to Volume 4
Current Cancer Drug Targets Osteoporotic Fracture Healing: Potential Use of Medicinal Plants from the Tropics
Current Drug Targets Thiazoles and Thiazolidinones as Antioxidants
Current Medicinal Chemistry Long Noncoding RNA MALAT1: Insights into its Biogenesis and Implications in Human Disease
Current Pharmaceutical Design Biological and Chemical Aspects of Natural Biflavonoids from Plants: A Brief Review
Mini-Reviews in Medicinal Chemistry GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Application of Fungal Beta-glucans for the Treatment of Colon Cancer
Anti-Cancer Agents in Medicinal Chemistry Recent Patents on Anti-Cancer Potential of Helenalin
Recent Patents on Anti-Cancer Drug Discovery Structure-Activity Relationships of Flavonoids
Current Organic Chemistry Epigallocatechin-3-gallate(EGCG): Mechanisms and the Combined Applications
Combinatorial Chemistry & High Throughput Screening The Potential of Flavonolignans in Prostate Cancer Management
Current Medicinal Chemistry Phytosterols in Cancer: From Molecular Mechanisms to Preventive and Therapeutic Potentials
Current Medicinal Chemistry